High Affinity Pharmacological Profiling of Dual Inhibitors Targeting RET and VEGFR2 in Inhibition of Kinase and Angiogeneis Events in Medullary Thyroid Carcinoma |
Dunna, Nageswara Rao
(School of Chemical and Biotechnology, SASTRA University)
Kandula, Venkatesh (Department of Genetics and Biotechnology, Osmania University) Girdhar, Amandeep (In silico Research Laboratory, Eminent Biosciences) Pudutha, Amareshwari (Department of Genetics and Biotechnology, Osmania University) Hussain, Tajamul (Center of Excellence in Biotechnology Research, College of Science, King Saud University) Bandaru, Srinivas (Genetics and Hospital for Genetic Diseases, Osmania University) Nayarisseri, Anuraj (In silico Research Laboratory, Eminent Biosciences) |
1 | Rougier P, Parmentier C, Laplanche A, et al (1983). Medullary thyroid carcinoma: prognostic factors and treatment. Int J Radiat Oncol Biol Phys, 9, 161-9 DOI |
2 | Samaan GA, Schultz PN, Hickey RC (1988). Medullary thyroid carcinoma: prognosis of familial versus sporadic disease and the role of radiotherapy. J Clin Endocrinol Metab, 67, 801-5. DOI |
3 | Santoro M and Carlomagno F (2006). Drug Insight: smallmolecule inhibitors of protein kinases in the treatment of thyroid cancer. Nat Clin Pract Endocrinol Metab, 2, 42-52 DOI |
4 | Schlumberger M, Carlomagno F, et al (2008). New therapeutic approaches to treat medullary thyroid carcinoma. Nat Clin Pract Endocrinol Metab, 4, 22-32. DOI |
5 | Thomsen R & Christensen MH (2006). MolDock: a new technique for high-accuracy molecular docking. J Med Chem, 49, 3315-21. DOI |
6 | Yeganeh MZ, Sheikholeslami S, & Hedayati M. (2015). RET proto oncogene mutation detection and medullary thyroid carcinoma prevention. Asian Pac J Cancer Prev, 16, 2107. DOI |
7 | Bandaru S, Ponnala D, Lakkaraju C, et al (2014). Identification of high affinity non-peptidic small molecule inhibitors of MDM2-p53 interactions through structure-based virtual screening strategies. Asian Pac J Cancer Prev, 16, 3759-3765. |
8 | Brozzo MS, Bjelić S, Kisko K, et al (2012). Thermodynamic and structural description of allosterically regulated VEGFR-2 dimerization. Blood, 119, 1781-8. DOI |
9 | Bandaru S, Tiwari G, Akka J, et al (2015). Identification of high affinity bioactive salbutamol conformer directed against mutated (Thr164Ile) beta 2 adrenergic receptor. Cur Top Med Chem, 15, 50-6. DOI |
10 | Brierley JD, Tsang R, Simpson WJ, et al. (1996) Medullary thyroid cancer: analyses of survival and prognostic factors and the role of radiation therapy in local control. Thyroid, 6, 305-10. DOI |
11 | Bunone G, Vigneri P, Mariani L, et al (1999). Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with pathological features. Am J Pathol, 155, 1967-76 DOI |
12 | Cheng F, Li W, Zhou Y, et al (2012). AdmetSAR: a comprehensive source and free tool for assessment of chemical ADMET properties. J Chem Inf Model, 52, 3099-105. DOI |
13 | DeSantis CE, Lin CC, Mariotto AB, et al (2014). Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin, 64, 252-71. DOI |
14 | Gilliland FD, Hunt WC, Morris DM, Key CR (1997). Prognostic factors for thyroid carcinoma: a population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program, 1973-1991. Cancer, 79, 564-73. DOI |
15 | Hundahl SA, Fleming ID, Fremgen AM, Menck HR (1996). A national cancer database report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer, 83, 2638-48. |
16 | Jorgensen WL, Maxwell DS & Tirado-Rives J (1996). Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids. J Am Chem Soc, 118, 11225-36. DOI |
17 | LigPrep, V. (2010). 2.4: Schrodinger. LLC, New York. |
18 | Kelotra S, Jain M, Kelotra A., Jain I, et al (2014). An in silico appraisal to identify high affinity anti-apoptotic synthetic tetrapeptide inhibitors targeting the mammalian caspase 3 enzyme. Asian Pac J Cancer Prev, 15, 10137. |
19 | Kilfoy BA, Zheng T, Holford TR, et al (2009). International patterns and trends in thyroid cancer incidence, 1973-2002. Cancer Causes Control, 20, 525-31. DOI |
20 | Knowles PP, Murray-Rust, et al (2006). Structure and chemical inhibition of the RET tyrosine kinase domain. J Biol Chem, 281, 33577-87. DOI |
21 | Marsh DJ, Learoyd DL, Robinson BG (1995). Medullary thyroid carcinoma: recent advances and managment update. Thyroid, 5, 407-20 DOI |
22 | Masbi MH, Mohammadiasl J, et al (2014). Characterization of wild-type and mutated RET proto-oncogene associated with familial medullary thyroid cancer. Asian Pac J Cancer Prev, 15, 2027-33. DOI |
23 | Maunz A, Gütlein M, Rautenberg M, et al (2013). Lazar: a modular predictive toxicology framework. Front Pharmacol, 4, 38. |
24 | Mitsiades CS, et al (2006). Epidermal growth factor receptor as a therapeutic target in human thyroid carcinoma: mutational and functional analysis. J Clin Endocrinol Metab, 91, 3662-6 DOI |
25 | Nelder JA & Mead R (1965). A simplex method for function minimization. Comput J, 7, 308-13. DOI |
26 | Petrangolini G, Cuccuru G, Lanzi C, et al (2006). Apoptotic cell death induction and angiogenesis inhibition in large established medullary thyroid carcinoma xenografts by Ret inhibitor RPI-1. Biochem Pharmacol, 72, 405-14 DOI |
![]() |